Effects of atorvastatin on some inflammatory markers in patients with multiple sclerosis treated by interferon beta-1b

Objective: To investigate the effect of Atorvastatin vs. placebo on some inflammatory markers in patients with multiple sclerosis treated by interferone beta-1b.To achieve the aim of this study, a randomized control comparative trial was adopted. Patients and Methods: A total of 100 patients with mu...

Full description

Saved in:
Bibliographic Details
Main Authors: Farah Waleed Mahmood (Author), Shamil Hashim Othman (Author)
Format: Book
Published: University of Mosul, 2019-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_df5f76ce6f5a484a8cace678db6e52e6
042 |a dc 
100 1 0 |a Farah Waleed Mahmood  |e author 
700 1 0 |a Shamil Hashim Othman  |e author 
245 0 0 |a Effects of atorvastatin on some inflammatory markers in patients with multiple sclerosis treated by interferon beta-1b 
260 |b University of Mosul,   |c 2019-06-01T00:00:00Z. 
500 |a 1680-2594 
500 |a 2664-2522 
500 |a 10.33899/iphr.2019.161191 
520 |a Objective: To investigate the effect of Atorvastatin vs. placebo on some inflammatory markers in patients with multiple sclerosis treated by interferone beta-1b.To achieve the aim of this study, a randomized control comparative trial was adopted. Patients and Methods: A total of 100 patients with multiple sclerosis were recruited and investigated for some inflammatory markers which included, interleukin-2, tumor necrosis factor-&alpha;, C-reactive protein, and erythrocyte sedimentation rate. The patients were divided into 2 groups, namely the atorvastatin group which consisted of 50 patients and the placebo group which consisted of 50 patients. The patient groups were followed- up for 12 weeks during which the above parameters were measured before starting therapies and at the end of the follow-up period using commercially available kits. The patient groups were compared with the control group consisted of 50 apparently healthy subjects. Results: The IL-2,TNF-&alpha;,CRP and ESR at baseline in both patient groups were found significantly elevated as compared with the control group ( p< 0.001) . The use of atorvastatinhas resulted in significant decrease on the above parameters with non-significant effects in the placebogroup. Atorvastatinappeared to be superior in compared with the placebo group. Conclusion: The use of atorvastatinfor 12 weeks in patients withmultiple sclerosis treated by interferone-beta has beneficial effect on some inflammatory markers studied in this research( IL-2,TNF-&alpha;,CRP and ESR). 
546 |a EN 
690 |a multiple sclerosis 
690 |a atorvastatin 
690 |a interferone-beta-1b 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n المجلة العراقية للصيدلة, Vol 14, Iss 1, Pp 23-31 (2019) 
787 0 |n https://iphr.mosuljournals.com/article_161191_82c204c1ff72855d6f02f26b448bde0c.pdf 
787 0 |n https://doaj.org/toc/1680-2594 
787 0 |n https://doaj.org/toc/2664-2522 
856 4 1 |u https://doaj.org/article/df5f76ce6f5a484a8cace678db6e52e6  |z Connect to this object online.